New drug combo tested in fight against advanced lung cancer
NCT ID NCT05664971
Summary
This study tested the safety and initial effectiveness of a new immunotherapy drug (JS004) when combined with an existing immunotherapy (toripalimab) and, for some patients, standard chemotherapy. It involved 119 adults with advanced non-small cell or small cell lung cancer that was not suitable for curative surgery or radiation. The main goals were to see how safe the combination was and if it could help shrink tumors or control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Conditions
Explore the condition pages connected to this study.